GlaxoSmithKline (GSK) announced Wednesday, that it will spend $229 million to settle lawsuits concerning deceptive marketing of its diabetes drug Avandia.

The company agreed to the settlement price with attorney generals of eight states: Kentucky, Louisiana, Maryland, Mississippi, New Mexico, South Carolina, Utah and West Virginia. The states chose not to take a settlement of $90 million offered in 2012, which resolved  Avandia-related consumer-protection claims by 37 other states, reports The Wall Street Journal.

Last year Glaxo pleaded guilty in federal court for failing to provide the Food and Drug Administration with clinical-trial information concerning Avandia. The company paid $3 billion to resolve federal investigations of the company, reports WSJ.

The $3 billion settlement is the largest to date in a health-care fraud case in the U.S., reports Bloomberg.

Avandia was removed from the European market in 2010, and has since been heavily restricted in the United States.